`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`ck VEGF
`
`protein of key domains
`human VEGFreceptors 1 and
`
`from
`
`2 with human IgG Fe Sieen necesmeeae
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708789
`
`Page2
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 3
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 4
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 5
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 6
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 7
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 8
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 9
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 10
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 11
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 12
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 13
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 14
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 15
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`*
`
`07/16/96
`
`Numberof injections in prn arm over 3-months
`(maximum of 3 possible)
`
`PRN Treatment Outcome
`Feeee
`
`Note: The 248 arm received 1 andthe q4 armsreceived 3 injections during this period.
`
`Forclarity, | would note on the PRN frequency chart that the 2mg q8 arm got
`1 additional injection at month4 visit and not month5visit.
`
`.
`
`CONFIDENTIAL
`
`16.
`
`RGN-EYLEA-MYLAN-00708803
`
`Page 16
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708804
`
`Page 17
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`SamsungBioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`17
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708805
`
`Page 18
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`SamsungBioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`18
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Most Frequent
`
`Oc
`
`Adver
`aCHL #
`
`1( 22%)|96.1%)
`
`j
`Riek.)
`yean ‘
`
`i
`
`17( 97%)
`atite
`RYieeie mht
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708806
`
`Page 19
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`19
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 20
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 21
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708809
`
`Page 22
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`SamsungBioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`22
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`
`
`CONFIDENTIAL
`
`RGN-EYLEA-MYLAN-00708810
`
`Page 23
`Exhibit2019
`Regeneron Pharmaceuticals, Inc.
`SamsungBioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
`IPR2023-00884
`
`23
`
`
`
`
`
`
`
`
`
`CONFIDENTIAL - PROTECTIVE ORDER MATERIAL
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2019 Page 24
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`